ASCO GU 2025 Prostate Cancer

Viewing 1-20 of 138 articles

ASCO GU 2025: Comparing Progression Following Systemic and Tumor-Directed Therapy for De Novo Versus Recurrent PSMA PET–defined Oligo-M1 Prostate Cancer: A Pooled Analysis of SOLAR and SATURN Clinical Trials

ASCO GU 2025: Beyond PSMA-Targeted Agents for Advanced Disease

ASCO GU 2025: PREP - A Prospective Provincial Registry of PSMA PET CT for Recurrent Prostate Cancer: Results for 4,135 Men

ASCO GU 2025: A Prospective Trial of a Structured Exercise Program to Lessen Fatigue in Patients with Advanced Prostate Cancer Undergoing ADT

ASCO GU 2025: Radium-223 Without ADT in Patients with Biochemically Recurrent Prostate Cancer and PET Findings in the Bones

ASCO GU 2025: Impact of Baseline PSMA PET in Patients with mCRPC Starting First-Line Androgen Receptor Signaling Inhibitor Therapy

ASCO GU 2025: ARASTEP: Darolutamide plus ADT in Patients with High-Risk Biochemical Recurrence of Prostate Cancer – a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

ASCO GU 2025: Implementation and Preliminary Validity of the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) in Patients Receiving Radionuclide Therapy for Prostate Cancer

ASCO GU 2025: SOAR: Phase II Trial of Image-Guided Oligometastatectomy and Radiation Therapy in Recurrent Prostate Cancer

ASCO GU 2025: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib in Combination with Androgen Receptor Pathway Inhibitors in Patients with mHSPC with and Without Homologous Recombination Repair Mutation

ASCO GU 2025: Outcomes for 177Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with mCRPC

ASCO GU 2025: Prospective Real World Data Evaluation of Clinical Outcomes in mHSPC Patients Treated as Part of Triplet Therapy with Darolutamide: UK Multicenter RECOmMEnD Study

ASCO GU 2025: Prostate Cancer Risk Groups by PSMA-PET PROMISE: Results from an International Multi-Center Registry Study

ASCO GU 2025: PSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing

ASCO GU 2025: PSA Response and Survival Based on Metastatic Site in Patients with mCRPC Treated with 177Lu-PSMA-617

ASCO GU 2025: Re-Treatment of mCRPC Patients with Radium-223 Therapy in Daily Practice

ASCO GU 2025: Secondary Outcomes by Prior Definitive Treatment in Patients with High-Risk Biochemically Recurrent Prostate Cancer Treated with Enzalutamide Monotherapy: EMBARK Post Hoc Analysis

ASCO GU 2025: Seeing Is Believing: Radiographic Criteria to Assess Response

ASCO GU 2025: Real-World Outcomes Among Patients with mCRPC Receiving Guideline-Recommended Therapies After Treatment with 177Lu-PSMA-617: A Real-World Prostate Cancer Disease Observation (PRECISION) Data Platform Analysis

ASCO GU 2025: Treatment Patterns in Prostate Cancer Patients Who Received Darolutamide in the ARAMIS Trial in Spain: PARASEC Study

1
2
3
4
5
6
7